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SUMMARY OF THE ORIGINAL ARTICLE 
Successful Homotransplantation of the Human Kidney 
Between Identical Twins 
John P. Merrill. MD; Joseph E. Murray. MD; 
J. Hartwell Harrison. MD; and Warren R. Guild. MD 
lAMA. 1956;160(4):277-282 
A patient whose illness had begun with edema and 
hypertension was found to have extreme atrophy of both 
kidneys. Because of the steady worsening of the condition and 
the appearance of uremia with other unfavorable diagnostic 
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D DRING THE DECADE BRACKEH.l) BY 1953 AND 1963, a beachhead for the clinical field of organ trans-plantation was established by a series of discov-
eries and events that included 3 milestone renal 
transplantations carried out by Murray and Merrill et al. l 
The first of these operations was performed with an iden-
tical twin's kidney on December 23, 1954, and published 
in JAMA 17 months later.! It already had been established 
that tissues were freely interchangeable between identical 
twins. In addition, the renal transplant procedure had been 
developed earlier in France by KUss, and subsequently used 
for the precedent-setting mother-to-son living kidney do-
nation reported in 1953 by Michon and Hamburger et al. 
Thus, the widely publicized case of 1954 would have had 
minimal, if any, unique implications if viewed in isolation. 
Instead, the landmark report by Merrill el all mobilized phy-
sician and public support for transplantation research to a 
new level. Only 12 years earlier, Medawar had shown with 
skin allografts that rejection was an immunologic phenom-
enon. By the early 19505, the main histopathologic features 
of renal allograft rejection in nonimmunosuppressed hu-
mans were delineated in studies of the kidney allograft of 
Michon and Hamburger, and of kidneys transplanted to the 
thigh by Hume and Merrill et a1. Successful engraftment of 
the identical twin kidney now dramatically demonstrated what 
could be accomplished if rejection were prevented. 
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signs, transplantation of 1 kidney from the patient's identical 
healthy twin brother was undertaken. Preparations included 
collection of evidence of monozygosity and experimental 
transplantation of a skin graft from the twin. During the transfer 
of the healthy kidney, it was totally ischemic for 82 minutes. 
Evidence of functional activity in the transplanted kidney was 
obtained. The hypertenSion persisted until the patient's diseased 
kidneys were both removed. The homograft has survived for 11 
months, and the marked dinical improvement in the patient has 
included disappearance of the signs of malignant hypertenSion. 
See www.jama.com for full text of the original lAMA artide. 
The only evidence that rejection might be avoidable 
had come from experiments reported in 1953 by Billing-
ham, Brent, and Medawar,2 in which allogeneic spleen 
cells were transplanted into immunologically immature 
mice. This was the forerunner model of bone marrow cell 
transplantation for humans with immune deficiency dis-
eases. In a second model that ultimately evolved into 
clinical bone marrow transplantation for a wide range of 
hematologic and other indications, Main and Prehn' 
reduced the immune responsiveness of adult mice by 
irradiation, preceding the transplantation of bone mar-
row cells. Under both experimental circumstances, the 
mouse recipients endowed with donor cells (ie, donor 
leukocyte chimerism) could accept other tissues from the 
same donor throughout their lifetime. 
A derivative 3-step strategy that could permit organ en-
graftment in patients was promptly envisioned. It con-
sisted of weakening the recipient'S immune system with total 
body irradiation as had been done by Main and Prehn, in-
fusing donor hematolymphopoietic (eg, bone marrow) cells, 
and engrafting an organ from the leukocyte donor. Efforts 
to apply this strategy in outbred large animals failed because 
the donor leukocytes either were rejected or caused graft-
vs-host disease. Human tissue antigens would not be suffi-
ciently delineated to avoid these outcomes by histocompat-
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Table. Characteristics of the First Successful Transplantations of Kidney Allografts With 2:6 mo Survival as of March 1963 
Physician Site Date Donor Relationship Outcome 
Joseph E. Murray Boston, Massachusetts January 24, 1959 Fratemal twin 20 Years 
Jean Hamburger Paris, France June 29, 1959 Fraternal twin 26 Years 
Rene KUss8 Paris, France June 22, 1960 Unrelated 18 Monthsb 
Jean Hamburgera Paris, France December 19,1960 Mother 22 Monthsb 
Rene KOssa Paris, France March 12, 1961 Unrelated 18 Monthsb 
Jean Hamburgera Paris, France February 1 2, 1 962 Cousin 15 Yearsc 
Joseph E. Murray Boston, Massachusetts April 5, 1962 Unrelated 17 Monthsd 
Thomas Starzl Denver, Colorado 1962-1963 Mixed series >45 Years 
a Kuss' ard Hamburger' described periodic admnistratioo of adrenal cortical steroids w~h these pat"nts. 
b Pat"nt death occurred at listed time. 
C Pat"nt underwent successful retranspantatkln In the 1970s; elected to French Parliament. 
d First success w~ drugs-ooly immunosuppresson (no radiatioo). 
ibility matching for another decade. Consequently, clinical 
bone marrow cell transplantation for any purpose was fore-
stalled until 1968. 
In contrast, kidney allografts were successfully trans-
planted in a small number of humans, beginning in 1959, with-
out donor leukocyte infusion or tissue matching. Success of 
these procedures was defined as life-supporting graft func-
tion for 1 year or more. In the first of these epochal cases, 
Merrill and Murray et a14 at the Peter Bent Brigham Hospital, 
Boston, Massachusetts, transplanted a kidney from a frater-
nal (dizygotic) twin to his sublethally irradiated brother (450 
R). Five months later, Hamburger et a1' duplicated the feat 
in a French fraternal twin (TABLE). Although 11 attempts by 
Merrill et al to move beyond fra ternal twins were unsuccess-
ful, 4 irradiated nontwin recipients were reported during 1960 
to 1962 by the Paris teams of Hamburger et at> and Kilss et 
a1.6 Two of the kidney donors were blood relatives and the 
other 2 were genetically unrelated (Table). 
The transplanted fraternal twin kidneys had normal func-
tion without post transplant immunosuppression until the re-
cipients died 20 and 26 years later of nonrenal causes. None 
of the nontwin kidneys were spared rejection, although one 
of these allografts (Table) functioned for 15 years.ln their non-
twin recipients in the Table, Hamburger and Kiiss described 
periodic administration of adrenal cortical steroids. In addi-
tion, Kilss secondarily administered the myelotoxic drug 6--mer-
captopurine to one patient as early as August 1960, based on 
canine studies of the drug in London, England, by Caine' who 
had visited the Paris, France, center in 1960 shortly before join-
ing Murray in Boston. 
The drug 6-mercaptopurine and its imidizole derivative 
azathioprine had been synthesized and shown to be immu-
nosuppressive by Elion and Hitchings in a search for anti-
leukemic agents. Interest in the use of these drugs for trans-
plantation was generated by a report of Schwartz and 
Dameshek in 1958 that a 2-week course of 6--mercaptopu-
rine inhibited the rabbit immune response to heterologous 
albumin. In 1959, they reported additional experiments 
showing that second and third albumin injections without 
further 6-mercaptopurine treatment failed to induce the typi-
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cal anamnestic response induced by repetitive exposure to 
foreign proteins.s This observation revealed the possibility 
of drug-assisted antigen-specific tolerance. In addition, when 
rabbits were given daily doses of 6-mercaptopurine, skin al-
lograft survival was prolonged but by only a few days. 
Moreover, when outbred canine kidney recipients were 
given daily doses of 6--mercaptopurine or its analogue aza-
thioprine, mean allograft survival was prolonged in most ani-
mals by only a few weeks. 7 Murray and Merrill et a19 then 
produced the seventh example of successful kidney allo-
graft transplantation, and the first ever with drugs only (with-
out irradiation, Table). The patient who received a kidney 
from an unrelated donor in April 1962 was treated daily with 
azathioprine to which adjunct cytotoxic agents were added. 
The milestone renal allograft functioned for 17 months be-
fore being rejected. 
Initial enthusiasm caused by news of this successful case 
was dampened when the recipient was the only one of the 
first 10 patients in the Boston azathioprine series to sur-
vive longer than 6 months. However, an overlapping series 
of living donor kidney transplantations in 1962 and 1963 
at the University of Colorado, Denver (Table), showed that 
renal transplantation could be a practical, albeit flawed, clini-
cal treatment when azathioprine was combined with pred-
nisone. lo The majority of these patients and their allografts 
(46 from blood relatives, 18 from unrelated individuals) sur-
vived more than 1 year. Close behind, Hume et al reported 
similar results in Richmond, Virginia, with a modified aza-
thioprine-prednisone combination. 
The Colorado experience revealed 2 features of the alloim-
mune response that permitted the rapid expansion of clinical 
renal transplantation, and because these features were not kid-
ney specific, the transplantation soon after of other organs. 
First, rejection that developed with azathioprine was revers-
ible with the addition of high doses of prednisone. Second, 
reversible r~ection frequently was succeeded by what was pro-
posed to be variable-acquired tolerance as evidenced by a time-
related reduction of need for immunosuppression. The need 
for maintenance immunosuppressive therapy eventually was 
eliminated in some patients. Eight recipients in this series cur-
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rently have the world's longest functioning organ allografts 
after 45 or more years, and 6 of the 8 have not taken immu-
nosuppression medications for 10 to 44 years. 
By the end of 1963, a base had been laid by the experi-
ence with kidney transplants that readily accommodated new 
immunosuppressive drugs (eg, antilymphocyte globulin, cy-
closporine, tacrolimus), and on which nomenal transplant 
programs would be built. What was missing was an under-
standing of what had been accomplished. None of the van-
guard kidney allograft recipients of 1959 to 1963 had been 
infused with donor lymphopoietic cells. It was assumed, 
therefore, that the requisite of donor leukocyte chimerism 
for tolerance in the mouse models played no role in organ 
engraftment. This dogma was not challenged until small 
numbers of multilineage donor leukocytes (microchime-
rism) were detected in 1992 in the tissues or blood of all 5 
kidney recipients of the 1962 to 1963 Colorado series who 
were studied, and of all 25 liver recipients who by 1992 were 
12 to 29 years posttransplantation. ll 
The microchimeric donor cells in these recipients were prog-
eny of the transplanted organ's passenger leukocytes of bone 
marrow origin. Under an umbrella of immunosuppression 
or without this protection in the radiated fraternal twins of 
1959, the ancestral donor leukocytes had migrated during the 
first few posttransplant weeks into the recipients. Thus, trans-
plantation of an organ was the equivalent of bone marrow 
cell infusion.'! Consistent with this view, Przepiorka and 
Thomas et aP2 contemporaneously discovered a small re-
sidual population of recipient cells (reverse microchime-
rism) in bone marrow recipients who previously were thought 
to have total hematolymphopoietic cell replacement. 
In the transplantation immunology paradigm that evolved 
from the microchimerism findings, it is axiomatic that stable 
alloengraftment of either an organ or bone marrow cells means 
that bidirectional tolerance has evolved-the completeness 
of which can be inferred by the amount of maintenance im-
munosuppression required to avoid rejection or graft-vs-
host disease. 11 The seminal tolerance mechanism of clonal ac-
tivation-exhaustion-deletion coincided with the rejection and 
its reversal first recognized in organ recipients in 1962 to 1963. 
The additional mechanism of "immune ignorance" essential 
for maintenance of exhaustion-deletion achieved with the ini-
tial flood of migratory leukocytes was first demonstrated in 
a skin transplantation model in 1968Y A third of a century 
passed, however, before the role of this passive mechanism 
of organ engraftment (failure of the immune system to rec-
ognize the presence of antigen that does not reach host lym-
phoid organs) was recognized. 
Concurrent with the microchimerism discoveries, Zinker-
nagel et al 14 independently formulated from infection stud-
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ies a similar explanation of acquired tolerance to viruses and 
other noncytopathic microorganisms. In 1998, the analo-
gies were described between essentially all clinical sce-
narios of transplantation and microorganism-specific in-
fection syndromes, with further linkages to the immunology 
of neoplasms and autoimmune disorders. 15 It was also pro-
posed as an overarching paradigm of immune regulation that 
immunologic responsiveness or unresponsiveness, no mat-
ter what the antigen, is governed by the migration and lo-
calization of the antigen. 
The therapeutic implications of these generalizable im-
munologic paradigms in other medical disciplines have only 
begun to be explored. In transplantation, the immediate re-
sult has been reducing the burden of chronic immunosup-
pression with revised treatment regimens in which the tim-
ing and doses of antirejection drugs interfere less with natural 
mechanisms of tolerance. 
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